Abstract 352P
Background
Breast cancer (BC) and its treatment could disturb the reproductive system. We identified reproductive system disorders following chemotherapy in patients with BC and the determinant factors.
Methods
One hundred and twelve married female patients with BC who underwent first chemotherapy between 2018 and 2020 in Dr. Sardjito Hospital, Yogyakarta were recruited. Socio-demographic and clinical data were collected at baseline. After each chemotherapy session, the patients were interviewed about symptoms of reproductive system disorder (irregular menstruation, vaginal dryness, decreased libido, dyspareunia, delayed orgasm and anorgasmia) and other symptoms (fatigue, anorexia, nausea and anxiety). We used a questionnaire based on the CTCAE version 4. Data of symptoms were collected until patients received at least 3 treatment cycles. Chi square and Fisher’s exact tests were used to analyze any association among variables.
Results
The most common symptoms were vaginal dryness (41.1%) followed by decreased libido (39.3%). In the subgroup analysis, the most common symptom among 44 pre-menopause women was irregular menstruation (84.1%). Vaginal dryness occurred more in cases with anthracycline-based regimen (p=0.036) and with anxiety (p=0.019), compared to their counterparts. Decreased libido presented more in cases with younger age (p=0.037) and positive ER status (p=0.009). Irregular menstruation, dyspareunia, delayed orgasm, and anorgasmia did not correlate with any of the determinant factors.
Conclusions
Reproductive system disorders occurred very frequently in the local BC patients after receiving chemotherapy. Influencing factors included anthracycline-based regimen, anxiety, age, and estrogen receptor status.
Clinical trial identification
Editorial acknowledgement
Erik Christopher Hookom, BA, M.Ed, TEFL Office of Research and Publication, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Legal entity responsible for the study
The authors.
Funding
The Indonesian Ministry of Research, Technology, and Higher Education; Public Funding, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session